ARTICLE | Targets & Mechanisms
EZH2 moves
October 18, 2012 7:00 AM UTC
Epizyme Inc. and GlaxoSmithKline plc have independently reported small molecule inhibitors of histone methyltransferase enhancer of zeste homolog 2 that showed efficacy in preclinical models of lymphomas with activating mutations of the target.1,2 Both companies plan to take inhibitors of the histone methyltransferase into the clinic in cancer.
Epizyme initially will focus on non-Hodgkin's lymphoma (NHL) patients with activating mutations in enhancer of zeste homolog 2 (EZH2). GSK declined to disclose how it will select a specific patient population. Neither company disclosed timing for an IND...